PHILADELPHIA (Reuters) - Johnson & Johnson on Wednesday said it may not complete its $25.4 billion purchase of Guidant Corp. < GDT.N>, saying the recall of products at the medical device maker had hurt the value of the company.
http://c.moreover.com/click/here.pl?r416312942
http://c.moreover.com/click/here.pl?r416312942